Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Gallia G Levy, Elina Asikanius, Peter Kuebler, Soraya Benchikh El Fegoun, Sille Esbjerg, Stephanie Seremetis, Gallia G Levy, Elina Asikanius, Peter Kuebler, Soraya Benchikh El Fegoun, Sille Esbjerg, Stephanie Seremetis

Abstract

Background: Recombinant activated factor VII (rFVIIa; eptacog alfa activated, NovoSeven® , Novo Nordisk A/S) is a bypassing agent used in congenital hemophilia A patients with inhibitors. Emicizumab (Hemlibra® ; F Hoffmann-La Roche Ltd) is a recombinant, humanized, bispecific monoclonal antibody used for routine prophylaxis in patients with congenital hemophilia A with inhibitors. Concomitant use of the hemostatic agents rFVIIa and emicizumab carries a theoretical increased risk of thrombotic complications. Roche and Novo Nordisk collaboratively analyzed all available data on the use of rFVIIa in patients receiving emicizumab prophylaxis in the Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN) clinical development program.

Objective: Obtain further insights into the concomitant clinical use and safety of rFVIIa and emicizumab.

Methods: The initial individual rFVIIa dose, dosing intervals and cumulative dosing were evaluated in the HAVEN 1, HAVEN 2, and HAVEN 4 trials. All adverse events reported in each of the three trials in patients treated with rFVIIa, including available narratives, were assessed.

Results: The vast majority of bleeds occurred in HAVEN 1. When rFVIIa was used to treat a bleeding episode, a 100 ± 20 μg/kg dose was used to initiate treatment in the majority of cases. The dosing interval, as well as cumulative dosing were consistent with prescribing information and current practice. No serious adverse events, no thrombotic microangiopathy cases, or thromboembolic events were assessed to be associated with rFVIIa when used in conjunction with emicizumab prophylaxis in the HAVEN trials.

Conclusion: rFVIIa use in the context of emicizumab prophylaxis does not change the rFVIIa safety profile as described in the product information.

Keywords: emicizumab; hemophilia A; recombinant FVIIa; safety.

© 2019 F. Hoffman La-Roche AG. Journal of Thrombosis and Haemostasis published by Wiley Periodicals Inc. on behalf of International Society on Thrombosis and Haemostasis.

References

REFERENCES

    1. FDA. Highlights of prescribing information - NovoSeven® RT, Coagulation Factor VIIa (Recombinant). Available at https://wwwfdagov/downloads//ucm056954pdf. 2014; Accessed 14 Sep 2018.
    1. EMA. NovoSeven summary of product characteristics. Available at http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873pdf. 2016; Accessed 14 Sep 2018.
    1. EMA. Summary of product characteristics - Hemlibra. Available at http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004406/WC500244743pdf. 2018; Accessed 14 Sep 2018.
    1. Adamkewicz JI, Muto A, Soeda T, Suzuki S, Kitazawa T. In vitro thrombin generation testing and in vivo venous stasis model for assessing the pro-coagulant effects of FVIII, emicizumab, rFVIIa, and aPCC. Haemophilia. 2017;23:11-27.
    1. Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIa-from molecular to clinical aspects of a versatile haemostatic agent. Thromb Res. 2010;125:483-9.
    1. Neufeld EJ, Negrier C, Arkhammar P, Benchikh el Fegoun S, Simonsen MD, Rosholm A, et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015;29(suppl 1):S34-41.
    1. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-18.
    1. Young G, Liesner R, Sidonio RF Jr, Oldenburg J, Jimenez-Yuste V, Mahlangu J, et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia Α with inhibitors: results from the HAVEN 2 study. Blood. 2018;132:632.
    1. Pipe S, Jimenez-Yuste V, Shapiro A, Key N, Podolak-Dawidziak M, Hermans C, et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with hemophilia A (PwHA) with and without inhibitors: results from Phase 3 HAVEN 4 study. Haemophilia. 2018;24:209-18.
    1. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809-18. Supplementary Material: Protocol. .
    1. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S45-9.
    1. Salek SZ, Benson GM, Elezovic I, Krenn V, Ljung RC, Morfini M, et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia. 2011;17:95-102.
    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. ; Treatment Guidelines Working Group The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-47.
    1. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia. 2009;15:83-90.
    1. Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 mug kg(-)(1)) rFVIIa doses across clinical trials and registries. Haemophilia. 2014;20:e23-31.
    1. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
    1. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14:898-902. HAE1829 [pii].
    1. Demartis F, Batorova A, Chambost H, Eshghi P, Karimi K, Kavakli K, et al. Real-world early treatment with room temperature-stable recombinant factor VIIa in hemophilia A/B and inhibitors: SMART-7™ post hoc analyses. TH Open. 2017;01:e130-8.
    1. NHF. MASAC Update on the Approval and Availability of the New Treatment: Emicizumab (Hemlibra), for Persons with Hemophilia A with Inhibitors to Factor VIII: Interim Guidance on Acute Bleed Management and Use of Laboratory Assays. Available at https://wwwhemophiliaorg/sites/default/files/MASAC-Update-on-the-Approval-and-Availability-of-the-New-Treatmentpdf. 2017; Accessed: 19 Sep 2018.
    1. Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018;24:344-7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren